Peptides Similar to Vesugen
Compare Vesugen with related peptides and alternatives
📌TL;DR
- •5 similar peptides identified
- •Pinealon: Both are Khavinson short tripeptides (3 residues each). Both co-tested in the PMID 34071923 5xFAD Alzheimer's mouse model with similar dose and route (400 mcg/kg/day intraperitoneal).
- •Prostamax: Vesugen is the N-terminal three residues of Prostamax. The two share the Lys-Glu-Asp motif and the broader Khavinson short-peptide framework.
Comparison chart of Vesugen and similar peptides
Infographic pending generation
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Vesugen (current) | - | - |
| Pinealon | Both are Khavinson short tripeptides (3 residues each). Both co-tested in the PMID 34071923 5xFAD Alzheimer's mouse model with similar dose and route (400 mcg/kg/day intraperitoneal). | Pinealon (EDR, Glu-Asp-Arg) is proposed for neural / cognitive function; Vesugen (KED, Lys-Glu-Asp) is proposed for vascular endothelium. Different N-terminal residue (Glu vs Lys) and different C-terminal residue (Arg vs Asp). |
| Prostamax | Vesugen is the N-terminal three residues of Prostamax. The two share the Lys-Glu-Asp motif and the broader Khavinson short-peptide framework. | Prostamax (KEDP, Lys-Glu-Asp-Pro) is a tetrapeptide proposed for prostate tissue; Vesugen (KED) is a tripeptide proposed for vascular endothelium. |
| Vilon | Vesugen is Vilon plus one C-terminal aspartate residue. Both are Khavinson short bioregulators. | Vilon (KE, Lys-Glu) is a dipeptide proposed for thymus / immune function; Vesugen (KED) is a tripeptide proposed for vascular endothelium. |
| Epitalon | Both are Khavinson short bioregulator peptides with central acidic residues (Glu, Asp). | Epitalon (AEDG, Ala-Glu-Asp-Gly) is a tetrapeptide proposed for pineal gland / telomerase activation; Vesugen (KED) is a tripeptide proposed for vascular endothelium. Different N- and C-termini. |
| Thymalin | Both are Khavinson-program preparations. | Thymalin is a thymus-derived multi-component peptide complex, not a single defined sequence. Vesugen is a single defined tripeptide. |
PinealonBoth are Khavinson short tripeptides (3 residues each). Both co-tested in the PMID 34071923 5xFAD Alzheimer's mouse model with similar dose and route (400 mcg/kg/day intraperitoneal).
Differences
Pinealon (EDR, Glu-Asp-Arg) is proposed for neural / cognitive function; Vesugen (KED, Lys-Glu-Asp) is proposed for vascular endothelium. Different N-terminal residue (Glu vs Lys) and different C-terminal residue (Arg vs Asp).
Advantages
Pinealon has a broader PubMed citation footprint (multiple neuroprotection and DNA-binding papers).
Disadvantages
Pinealon is not targeted at vascular endothelium per the Khavinson framework.
ProstamaxVesugen is the N-terminal three residues of Prostamax. The two share the Lys-Glu-Asp motif and the broader Khavinson short-peptide framework.
Differences
Prostamax (KEDP, Lys-Glu-Asp-Pro) is a tetrapeptide proposed for prostate tissue; Vesugen (KED) is a tripeptide proposed for vascular endothelium.
Advantages
Vesugen has the stronger published PubMed evidence (PMID 34071923 vs Prostamax's PMID 15612551 in-vitro lymphocyte study).
Disadvantages
Vesugen does not address prostate biology.
VilonVesugen is Vilon plus one C-terminal aspartate residue. Both are Khavinson short bioregulators.
Differences
Vilon (KE, Lys-Glu) is a dipeptide proposed for thymus / immune function; Vesugen (KED) is a tripeptide proposed for vascular endothelium.
Advantages
Vilon has multi-decade Khavinson-program clinical reports.
Disadvantages
Vilon is a different proposed target tissue.
EpitalonBoth are Khavinson short bioregulator peptides with central acidic residues (Glu, Asp).
Differences
Epitalon (AEDG, Ala-Glu-Asp-Gly) is a tetrapeptide proposed for pineal gland / telomerase activation; Vesugen (KED) is a tripeptide proposed for vascular endothelium. Different N- and C-termini.
Advantages
Epitalon has the largest published Khavinson literature footprint.
Disadvantages
Epitalon's evidence base is still concentrated in the Khavinson program and lacks independent replication.
ThymalinBoth are Khavinson-program preparations.
Differences
Thymalin is a thymus-derived multi-component peptide complex, not a single defined sequence. Vesugen is a single defined tripeptide.
Advantages
Thymalin has multi-decade Russian clinical-use experience.
Disadvantages
Thymalin is not a defined chemical entity; cross-batch composition can vary; not directly comparable to a single defined sequence.
Similarities and differences between Vesugen and related peptides
Infographic pending generation
Peptides Similar to Vesugen (KED): Khavinson Bioregulator Family#
Vesugen sits within the Khavinson short-peptide bioregulator family. Its closest analogues -- by sequence or co-citation -- are summarised below. For evidence-based cardiovascular prevention, the relevant comparison is not other peptides but standard pharmacological and lifestyle interventions.
Khavinson Short-Peptide Family#
| Peptide | Sequence | Length | Proposed Target Tissue | PubMed Footprint |
|---|---|---|---|---|
| Vesugen | KED | 3 | Vascular endothelium | PMID 34071923 (co-tested with EDR in 5xFAD mice) |
| Pinealon | EDR | 3 | Neural tissue | Multiple PMIDs (incl. 34071923, 22117547) |
| Epitalon | AEDG | 4 | Pineal gland | Largest in the family |
| Vilon | KE | 2 | Thymus / immune | Multiple reports |
| Prostamax | KEDP | 4 | Prostate | 1 in-vitro citation (PMID 15612551) |
| Thymalin | (complex) | -- | Thymus | Multi-decade Russian clinical use |
Sequence Relatives#
Vesugen is sequence-related to:
- Vilon (KE) -- Vesugen extends Vilon by one C-terminal aspartate
- Prostamax (KEDP) -- Vesugen is the N-terminal three residues of Prostamax
This pattern -- KE → KED → KEDP -- is consistent with the Khavinson program's broader claim that small changes in short-peptide sequence confer different tissue-selective gene-regulatory activity. Independent biophysical evidence supporting this claim is limited.
Co-Citation Relatives#
Vesugen and Pinealon (EDR) were co-administered in the canonical Vesugen citation (Khavinson 2021; PMID 34071923; Pharmaceuticals)1. The two were given at 400 mcg/kg/day intraperitoneally in 5xFAD mice from 2-4 months of age. The paper reports their combined effect on dendritic spine preservation, with separate in-silico docking predictions for each peptide's binding partners. For most readouts, the individual contribution of KED versus EDR cannot be cleanly separated in the reported data.
Conventional Cardiovascular Prevention Comparison#
For vascular aging and cardiovascular prevention, the standard evidence-based options include:
- Blood-pressure control (ARBs, ACEIs, calcium-channel blockers, thiazides) -- decades of mortality and MACE data
- Statins (atorvastatin, rosuvastatin) -- mortality, MACE, stroke benefit demonstrated
- Aspirin (for secondary prevention; primary prevention debated)
- Lifestyle (exercise, Mediterranean-pattern diet, smoking cessation) -- meta-analytic mortality benefit
- PCSK9 inhibitors for high-risk dyslipidaemia
All of these have multi-decade randomised trial evidence with hard cardiovascular endpoints. Vesugen has a single PubMed-indexed mouse study with a neurological endpoint. The two evidence bases are not on the same scale.
Bottom Line#
Vesugen's closest sequence relatives are Vilon (KE) and Prostamax (KEDP); its closest co-citation relative is Pinealon (EDR). None of these is an FDA-approved drug. For vascular-aging concerns, evidence-based cardiovascular prevention is the appropriate first-line approach.
References#
Related Reading#
- Pinealon overview
- Prostamax overview
- Epitalon overview
- Vilon overview
- Thymalin overview
- Vesugen research base
Footnotes#
-
Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. Neuroprotective Effects of Tripeptides -- Epigenetic Regulators in Mouse Model of Alzheimer's Disease. Pharmaceuticals. 2021. PMID: 34071923. DOI: 10.3390/ph14060515. ↩
Frequently Asked Questions About Vesugen
What's the closest Khavinson peptide to Vesugen?
Sequence-wise, Vilon (KE) and Prostamax (KEDP) are the closest -- Vilon is the first two residues of Vesugen, and Vesugen is the first three residues of Prostamax. By proposed mechanism and co-citation, Pinealon (EDR) is the closest -- it was co-tested with Vesugen in PMID 34071923.
Should I use Vesugen instead of cardiovascular medication?
No. Evidence-based cardiovascular therapy (blood-pressure control, statins where indicated, aspirin where indicated, lifestyle modification) has multi-decade randomised trial evidence with hard cardiovascular endpoints (MACE, mortality). Vesugen has a single PubMed-indexed mouse study with a neural endpoint and no human cardiovascular trial data. The two cannot be compared on evidence quality.
Can Vesugen be stacked with Pinealon (EDR)?
The PMID 34071923 study explicitly co-administered KED (Vesugen) with EDR (Pinealon) at 400 mcg/kg/day intraperitoneal in mice and reported no acute adverse effects, but did not separate their individual contributions for all endpoints. This is not endorsement of a stack in humans; no human stack safety or efficacy data exist.
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer